Under the plans, secondary packaging capabilities for ULT products will be added and capabilities to handle biopharmaceuticals and advanced modalities will be increased

syringe-ga1f24bda2_1920

Catalent invests $2.2m to expand clinical supply facility in Singapore. (Credit: Arek Socha from Pixabay)

Catalent, a US-based provider of delivery technologies, has announced an investment of $2.2m to expand its clinical supply facility in Singapore.

The investment will allow the installation of 35 new freezers for ultra-low temperature (ULT) storage, expanding the site’s footprint by over 20% to 31,000ft².

Under the expansion plans, specialised secondary packaging capabilities for ULT products will be added to allow the site’s services to support larger packaging campaigns.

In addition, the expansion will increase the site’s capacity to handle biopharmaceuticals and advanced modalities, such as mRNA-based vaccines, and cell and gene therapies.

Catalent APAC Clinical Development & Supply vice president and general manager Roel de Nobel said: “Our Singapore site serves as a strategic supply hub for the Asia-Pacific market, offering a wide range of services to customers in over 20 countries in the region.

“As the site prepares to mark its 25-year anniversary, this is the latest in a series of investments and expansions that it has undertaken to meet the increasing and diversified demands of customers in their mission to develop life-changing medicines for both the region and the world.”

Catalent’s site in Singapore, in addition to its locations in China and Japan, provides a wide range of clinical supply services to the Asia-Pacific region.

The services include clinical supply management, comparator sourcing, Catalent’s FastChain demand-led supply solution, secondary packaging, storage, and international distribution, as well as clinical returns and destruction.

In June this year, the company upgraded the primary packaging capabilities of its clinical supply facility in Shiga, Japan.